Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies

Annals of Oncology

Volumn 19, Issue 2, 2008, Pages 374-379

  Jimeno, A ^a   Messersmith, W A ^a   Lee, C K ^a   Ma, W W ^a   Laheru, D ^a   Donehower, R C ^a   Baker, S D ^a   Hidalgo, M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Continuous infusion; PK modeling; Troxacitabine

Indexed keywords

CARBOPLATIN; CISPLATIN; MITOMYCIN C; NITROSOUREA; SPD758; TROXACITABINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; APPENDIX CANCER; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER CANCER; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOCALCEMIA; KIDNEY CARCINOMA; LIVER CANCER; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PLASMA CELL GRANULOMA; PRIORITY JOURNAL; PRURITUS; RASH; SALIVARY GLAND CANCER; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; UTERUS CANCER;

ADULT; AGED; CYTOSINE; DIOXOLANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROBABILITY; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 38849154117     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm572     Document Type: Article

References (13)

1. Belanger K, Moore M, Baker SD et al. Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. J Clin Oncol 2002; 20: 2567-2574.
2. de Bono JS, Stephenson J, Jr., Baker SD et al. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: A phase I and pharmacolkinetic study in patients with advanced solid malignancies. J Clin Oncol 2002; 20: 96-109.
3. Siu LL, Attardo G, Izbicka E et al. Activity of (-)-2′-deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann Oncol 1998; 9: 885-891.
4. Gourdeau H, Genne P, Kadhim S et al. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts. Cancer Chemother Pharmacol 2002; 50: 490-496.
5. Gourdeau H, Leblond L, Hamelin B et al. Species differences in troxacitabine pharmacokinetiGs and pharmacodynamics: Implications for clinical development. Clin Cancer Res 2004; 10: 7692-7702.
6. Giles FJ, Cortes JE, Baker SD et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 2001; 19: 762-771.
7. Giles FJ, Garcia-Manero G, Cortes JE et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 2002; 20: 656-664.
8. Roboz GJ, Giles FJ, Ritchie EK et al. Phase I/II study of continuous-infusion troxacitabine in refractory -acute myeloid leukemia. J Clin Oncol 2007; 25: 10-15.
9. Townsley CA, Chi K, Ernst DS et al. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2003; 21. 1524-1529.
10. Lapointe R, Letourmeau R, Steward W et al. Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: Gastrointestinal tumors. Ann Oncol 2005; 16: 289-293.
11. Dent SF, Arnold A, Stewart DJ et al. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer. Lung 2005; 183: 265-272.
12. Lee CK, Rowinsky EK, LI J et al. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clin Cancer Res 2006; 12: 2158-2165.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.